Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C, Largeaud L, Bertoli S. Gondran C, et al. Among authors: sarry a. Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Leroy H, Gadaud N, Bérard E, Klein E, Luquet I, Vial JP, Rieu JB, Lechevalier N, Tavitian S, Leguay T, Largeaud L, Bidet A, Delabesse E, Sarry A, de Grande AC, Récher C, Pigneux A, Bertoli S, Dumas PY. Leroy H, et al. Among authors: sarry a. Cancer Med. 2024 Feb;13(3):e7003. doi: 10.1002/cam4.7003. Cancer Med. 2024. PMID: 38400682 Free PMC article.
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, Bidet A, Rieu JB, Luquet I, Lechevalier N, Delabesse E, Sarry A, De Grande AC, Bérard E, Pigneux A, Récher C, Simoncini D, Bertoli S. Didi I, et al. Among authors: sarry a. Leuk Res. 2024 Jan;136:107437. doi: 10.1016/j.leukres.2024.107437. Epub 2024 Jan 9. Leuk Res. 2024. PMID: 38215555 Free article.
Vitamin C and D supplementation in acute myeloid leukemia.
Mouchel PL, Bérard E, Tavitian S, Gadaud N, Vergez F, Rieu JB, Luquet I, Sarry A, Huguet F, Largeaud L, Delabesse E, Huynh A, Bertoli S, Récher C. Mouchel PL, et al. Among authors: sarry a. Blood Adv. 2023 Nov 28;7(22):6886-6897. doi: 10.1182/bloodadvances.2023010559. Blood Adv. 2023. PMID: 37671973 Free PMC article.
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.
Vergez F, Largeaud L, Bertoli S, Nicolau ML, Rieu JB, Vergnolle I, Saland E, Sarry A, Tavitian S, Huguet F, Picard M, Vial JP, Lechevalier N, Bidet A, Dumas PY, Pigneux A, Luquet I, Mansat-De Mas V, Delabesse E, Carroll M, Danet-Desnoyers G, Sarry JE, Récher C. Vergez F, et al. Among authors: sarry a. Blood Cancer J. 2022 Aug 16;12(8):117. doi: 10.1038/s41408-022-00712-7. Blood Cancer J. 2022. PMID: 35973983 Free PMC article.
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Gadaud N, Leroy H, Bérard E, Tavitian S, Leguay T, Dimicoli-Salazar S, Rieu JB, Luquet I, Largeaud L, Bidet A, Delabesse E, Klein E, Sarry A, de Grande AC, Bories P, Pigneux A, Récher C, Dumas PY, Bertoli S. Gadaud N, et al. Among authors: sarry a. Leuk Lymphoma. 2022 Jun;63(6):1398-1406. doi: 10.1080/10428194.2021.2022140. Epub 2022 Jan 4. Leuk Lymphoma. 2022. PMID: 35634787
Genomic landscape of hyperleukocytic acute myeloid leukemia.
Largeaud L, Bertoli S, Bérard E, Tavitian S, Picard M, Dufrechou S, Prade N, Vergez F, Rieu JB, Luquet I, Sarry A, Huguet F, Ruiz J, De Mas V, Delabesse E, Récher C. Largeaud L, et al. Among authors: sarry a. Blood Cancer J. 2022 Jan 5;12(1):4. doi: 10.1038/s41408-021-00601-5. Blood Cancer J. 2022. PMID: 34987148 Free PMC article. No abstract available.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: sarry a. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, Luquet I, De Mas V, Filleron T, Cassou M, Sarry A, Fornecker LM, Simand C, Bertoli S, Recher C, Delabesse E. Bories P, et al. Among authors: sarry a. PLoS One. 2020 Oct 1;15(10):e0238795. doi: 10.1371/journal.pone.0238795. eCollection 2020. PLoS One. 2020. PMID: 33001991 Free PMC article.
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, Prade N, Dufrechou S, Plenecassagnes J, Luquet I, Blanchet O, Banos A, Béné MC, Bernard M, Bertoli S, Bonmati C, Fornecker LM, Guièze R, Haddaoui L, Hunault M, Ianotto JC, Jourdan E, Ojeda M, Peterlin P, Vey N, Zerazhi H, Yosr H, Mineur A, Cahn JY, Ifrah N, Récher C, Pigneux A, Delabesse E; French Innovative Leukemia Organization (FILO). Largeaud L, et al. Leukemia. 2021 May;35(5):1291-1300. doi: 10.1038/s41375-020-01031-1. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32943750 Clinical Trial.
34 results